Thane Wettig - Chief Executive Officer Mark Eisner - Chief Medical Officer Operator Joining me on today's call are Thane Wettig, our Chief Executive Officer; Juan Graham, our Chief Financial Officer; Dr. Mark Eisner, our Chief Scientific Officer and Chris Chung, our Senior Vice President of China Operations. Following our prepared remarks, we will open the call to your questions. With that, I would like to turn the call over to Thane Wettig. Thanks Dave, and good afternoon, everyone. Welcome to our third qu ...

Significant commercial potential • PDAC: Safe and well tolerated with dose and exposure-related response, trend for improved resection rate, and increased completion of chemotherapy cycles • Phase 3 programs in areas of high unmet medical need with limited late-stage competitive intensity • PDAC: Multi-billion-dollar revenue opportunity, if successful 5 Recently Announced and Upcoming Pamrevlumab Milestones 3Q 2023 1H 2024 • Announced negative topline results from phase 3 LELANTOS-2 trial in ambulatory DMD ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, INC. (Exact name of registrant as specified in its charter) Delaware 77-0357827 (State or Other Jurisdictio ...

FibroGen, Inc. (NASDAQ:FGEN) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Enrique Conterno - Chief Executive Officer Juan Graham - Chief Financial Officer Joining me on today's call are Thane Wettig, Interim Chief Executive Officer; Juan Graham our Chief Financial Officer; Dr. Mark Eisner, our Chief Medical Officer; Dr. John Hunter, our Chief Scientific Officer; Chris Chung, our Senior Vice President of China Operations and Enrique Conterno, our outgoing Chief Executive Of ...

FibroGen Reports Second Quarter 2023 Financial Results August 7, 2023 Forward-Looking Statements 2 This presentation contains forward-looking statements regarding FibroGen's strategy, future plans and prospects, including statements regarding the development and commercialization of the company's product candidates, the potential safety and efficacy profile of its product candidates, and its clinical programs. These forward-looking statements include, but are not limited to, statements under the caption "Up ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, INC. (Exact name of registrant as specified in its charter) Delaware 77-0357827 (State or Other Jurisdiction of ...

Michael Tung - Vice President, Corporate Strategy & Investor Relations Enrique Conterno - Chief Executive Officer Juan Graham - Chief Financial Officer Mark Eisner - Chief Medical Officer John Hunter - Chief Scientific Officer Conference Call Participants Company Participants I would now like to hand the conference over to your speaker today, Michael Tung. Please go ahead. Thank you, Eleanor, and good afternoon everyone. I'm Michael Tung, Vice President of Corporate Strategy and Investor Relations at FibroG ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36740 FIBROGEN, INC. (Exact name of registrant as specified in its charter) Delaware 77-0357827 (State or Other Jurisdiction of ...

Forward-Looking Statements Forward-looking statements involve known and unknown risks, uncertainties, assumptions, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements, including the other risks and uncertainties that are described in the Risk Factors section of our most recent annual report on Form 10-K or quarterly report on Form 10-Q filed wi ...

Operator I would now like to hand the call over to your host, Mike Tung. Please go ahead. Thank you, Latif, and good afternoon, everyone. I'm Michael Tung, Vice President of Corporate Strategy and Investor Relations at FibroGen. Joining me on today's call are Enrique Conterno, our Chief Executive Officer; Dr. Mark Eisner, our Chief Medical Officer; Juan Graham, our Chief Financial Officer; Dr. John Hunter, our Chief Scientific Officer; Thane Wettig, our Chief Commercial Officer; and Chris Chung, our Senior ...